Could a leukemia drug stop deadly brain tumor spread?

NCT ID NCT07039760

Not yet recruiting Knowledge-focused Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 3 times

Summary

This early study tests whether asciminib, a drug already approved for leukemia, can get into brain tumors in children and young adults (ages 6-25) with recurrent brain tumors. Some participants will also get sildenafil to see if it helps the drug enter the tumor. The main goal is to measure drug levels in tumor tissue after surgery, not to treat the tumor itself.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: asciminib with or without sildenafil
What this could lead to: If it works, this could point toward a way to treat brain tumors that have spread, by helping the drug reach the tumor in higher amounts.
What could go wrong: This is a very early, small study (12 people) that only measures drug levels in the tumor, not whether the drug actually shrinks tumors or improves survival. It may not lead to a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer brain neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN TUMOR

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Washington University School of Medicine/St. Louis Children's Hospital

St Louis, Missouri, 63110, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.